BioSphere Medical Receives Market Clearance to Sell Embosphere® Microspheres in the People’s Republic of China

BioSphere’s State-of-the-Art Embolic Now Available to the World’s Largest Population of Patients with Primary Liver Cancer Tumors
ROCKLAND, Mass.--(BUSINESS WIRE)--BioSphere Medical, Inc. (Nasdaq: BSMD), a medical device company that has pioneered the use of bioengineered microspheres to treat uterine fibroids, hypervascularized tumors, and vascular malformations by a minimally invasive, image-guided medical procedure called embolotherapy, today reported that the Medical Device Department of the State Food and Drug Administration of the People’s Republic of China has approved BioSphere’s Embosphere Microspheres for clinical use for vascular embolizations, arteriovenous malformations, hypervascularized tumors, and symptomatic uterine fibroids. BioSphere expects to commence shipments of Embosphere Microspheres to China in the first quarter of 2008.

press release >> http://www.businesswire.com/portal/site/google/index.jsp?ndmViewId=news_view&newsId=20080128005699&newsLang=en